biomosaics 产品代理
biomosaics 产品代理
我们将用于癌症早期检测的生物标志物分析和试剂商业化，用于临床和研究环境。我们自豪地为您提供可靠且始终如一的产品；你可以信赖的产品。我们的产品和服务重点：IHC一级抗体在癌症诊断中的临床应用选择免疫分析，有望用于未满足需求的肿瘤领域，包括体细胞突变和遗传损伤的生物标志物。
我们的产品和服务重点：
IHC一级抗体在癌症诊断中的临床应用
选择免疫分析，有望满足未满足需求的肿瘤学领域
体细胞突变和遗传损伤的生物标志物
用89Zr标记的抗glypican-3单克隆抗体成像肝细胞癌。
免疫PET是一种利用正电子发射断层扫描（PET）相机对单克隆抗体进行跟踪和量化的技术，它是一项提高癌症检测能力的激动人心的创新。免疫PET最近在技术发展方面已达到成熟，目前正进入大规模临床应用阶段。我们目前正在与斯坦福大学合作开发89Zr标记的抗glypican-3单克隆抗体，作为肝细胞癌的诊断显像剂。
Glypican 3 Antibodies
Primary Antibodies
Immunohistochemistry Kits
ELISA Kits
BioMosaics is a leading provider of diagnostic immunohistochemistry products.
We commercialize biomarker assays and reagents for the early detection of cancer, for use in clinical and research settings. We take pride in providing you with products that are reliable and consistent; products you can depend on. Our product and service focus: primary antibodies for IHC with clinical utility for the diagnosis of cancer select immunoassays with promise for oncologic areas of unmet need biomarkers of somatic mutation and genetic damage.
Our product and service focus:
Primary antibodies for IHC with clinical utility for the diagnosis of cancer
Select immunoassays with promise for oncologic areas of unmet need
Biomarkers of somatic mutation and genetic damage
Imaging hepatocellular carcinoma using 89Zr-labeled anti-glypican-3 monoclonal antibody.
Immuno-PET, the tracking and quantification of monoclonal antibodies using positron emission tomography (PET) cameras, is an exciting innovation to increase the ability to detect cancer. Immuno-PET has recently reached maturity in terms of technical development and is now entering the phase of broad-scale clinical application. We are currently developing our 89Zr-labeled anti-glypican-3 monoclonal antibody as a diagnostic imaging agent for hepatocellular carcinoma through a collaboration with Stanford University.
